A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

Status:
Recruiting

Trial end date:
2025-09-12

Target enrollment:

Participant gender:

To evaluate the safety and tolerability of AMG 757 and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Phase 1

Amgen